Abstract:Chemotherapy and endocrine therapy are important components of systemic therapy for hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer, which can significantly improve the prognosis of patients. Based on early evidence-based medical evidence, domestic and foreign guidelines recommend sequential endocrine therapy rather than concurrent chemotherapy for breast cancer. However, with the deepening of the understanding of tumor biological behavior, the development of new drugs, and the updating of treatment methods, concurrent treatment may have its unique therapeutic advantages, which has once again aroused the interest of scholars. This article will review the latest progress and applicable time of endocrine therapy in the chemotherapy of HR positive HER2 negative breast cancer from two aspects of basic research and clinical research (including late rescue therapy, locally advanced neoadjuvant therapy and early adjuvant therapy).